© 2019 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.
More than 40% of people treated with enfortumab vedotin experienced complete or partial remission.
Antibody-drug conjugate carries a chemotherapy drug directly to cancerous B cells.
AMG 510 shrank tumors in half of lung cancer patients with a mutation thought to be “undruggable.”
Piqray plus Faslodex prolonged progression-free survival for metastatic breast cancer patients with PIK3CA gene mutation.
There are now five targeted therapies for the most common type of liver cancer.
Study found Venclexta plus Gazyva (obinutuzumab) delayed disease progression in previously untreated patients.
Most people who received Rubraca maintenance therapy experienced tumor regression or had stable disease.
The method identifies which targeted therapies, inadequate on their own, can be paired up to kill non-responsive cancers.
Umbralisib may offer a chemotherapy-free option for people with relapsed or nonresponsive marginal zone lymphoma.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.
